First Patient Safely Combine Dosed in Phase 1 RC220 Trial
Released 18 Jun 25
Latest announcements
Announcement summary
First Patient Safely Combine Dosed in Phase 1 RC220 Trial
Ask a question
Your question will be sent privately to Race Oncology. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Race Oncology a question about this announcement.